Caris Life Sciences, Inc.

CAI

Precision medicineHealthcare diagnosticsGenomic analysis

$26.30vs prev close▲+0.03(+0.11%)

$14.1952W Range$40.40

46% from low

+10.73 (+69.14%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.07%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -100.0% · Market value -100.0% · Weight -0.07%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.06	SELL	ARKG	93	$18.59	$1.7K
26.03.05	SELL	ARKG	1,501	$19.22	$28.8K
26.03.04	SELL	ARKG	11,732	$19.86	$233.0K
26.03.03	SELL	ARKG	376,505	$19.38	$7.3M
25.12.17	BUY	ARKG	35,111	$27.19	$954.7K
25.12.16	BUY	ARKG	33,247	$27.60	$917.6K
25.11.06	BUY	ARKG	92,072	$24.61	$2.3M
25.08.12	BUY	ARKG	60,533	$32.46	$2.0M
25.07.18	BUY	ARKG	13,036	$30.19	$393.6K
25.07.17	BUY	ARKG	14,708	$31.28	$460.1K
25.07.16	BUY	ARKG	23,153	$31.40	$727.0K
25.07.15	BUY	ARKG	37,290	$28.91	$1.1M
25.07.14	BUY	ARKG	52,527	$27.72	$1.5M
25.06.18	BUY	ARKG	49,142	$28.00	$1.4M

03.06SELL

ARKGClose$18.59Est. total$1.7K

03.05SELL

1,501

ARKGClose$19.22Est. total$28.8K

03.04SELL

11,732

ARKGClose$19.86Est. total$233.0K

03.03SELL

376,505

ARKGClose$19.38Est. total$7.3M

12.17BUY

35,111

ARKGClose$27.19Est. total$954.7K

12.16BUY

33,247

ARKGClose$27.60Est. total$917.6K

11.06BUY

92,072

ARKGClose$24.61Est. total$2.3M

08.12BUY

60,533

ARKGClose$32.46Est. total$2.0M

07.18BUY

13,036

ARKGClose$30.19Est. total$393.6K

07.17BUY

14,708

ARKGClose$31.28Est. total$460.1K

07.16BUY

23,153

ARKGClose$31.40Est. total$727.0K

07.15BUY

37,290

ARKGClose$28.91Est. total$1.1M

07.14BUY

52,527

ARKGClose$27.72Est. total$1.5M

06.18BUY

49,142

ARKGClose$28.00Est. total$1.4M

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Philippe LaffontCoatue Management

Increased

9,819,992

Portfolio Weight

7.56%

Est. Value

$265M

vs Prev Quarter

+11012% (88K→9.8M)

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

Est. Sold Value

$2K

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$27.00

vs Current ▲ +2.8% upside

Current$26.27

Low ~ High$22.00 ~ $36.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Evercore ISI Group

Outperform

$26.00

-1.03%

—

Maintain

2026-08-06

BTIG

Buy

$33.00

+25.62%

—

Maintain

2026-08-06

Evercore ISI Group

Outperform

$25.00

-4.83%

—

Maintain

2026-07-06

BTIG

Buy

$32.00

+21.81%

—

Maintain

2026-07-02

Citigroup

Buy

$28.00

+6.59%

—

Maintain

2026-05-08

1 / 4

Avg Target

$27.00

vs Current ▲ +2.8% upside

Buy

13 analysts

Strong Buy 1Buy 9Hold 3

Low $22.00

Current $26.27

High $36.00

Firm	Position	Target	Upside	Close	Action	Date
Evercore ISI Group	Outperform	$26.00	-1.03%	—	Maintain	26.08.06
BTIG	Buy	$33.00	+25.62%	—	Maintain	26.08.06
Evercore ISI Group	Outperform	$25.00	-4.83%	—	Maintain	26.07.06
BTIG	Buy	$32.00	+21.81%	—	Maintain	26.07.02
Citigroup	Buy	$28.00	+6.59%	—	Maintain	26.05.08

1 / 4

Price Information

Previous Close$24.58

Open$24.77

Day Range$24.32 - $26.60

52-Week Range$14.19 - $40.40

1-Year Change-31.73%

Trading Volume

Volume6,389,323

Avg Volume (3mo)3,791,496

Valuation

Market Cap7.4B

Book Value$2.09

Shares Outstanding282,680,695

Financials

Revenue (TTM)989.6M

Net Income105.1M

EPS$9.58

EBITDA174.0M

Profitability

P/E Ratio2.74

P/B Ratio12.55

Return on Equity (ROE)20.13%

Return on Assets (ROA)8.77%

Profit Margin10.62%

EV/EBITDA40.70

Beta-

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)82.62

Company Overview

Caris Life Sciences is an AI-powered TechBio company specializing in molecular profiling services for cancer treatment. Their main offerings include tissue-based (MI Profile) and blood-based (Caris Assure) molecular profiling, alongside R&D services for biopharmaceutical clients. They are also developing a multi-cancer early detection assay, positioning themselves at the forefront of precision medicine.

P/B

12.55

High valuation

ROE

20.1%

High return

Beta

Market Volatility

RSI(14)

82.6

Overbought

AI-generated summary. Not investment advice.

Caris Life Sciences, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks